Viscosupplementation Market Expected to Hit USD 15.26 Billion by 2034 | CAGR: 10.1%

Market Overview

The global viscosupplementation market was valued at USD 5.81 billion in 2024 and is projected to grow from USD 6.39 billion in 2025 to USD 15.26 billion by 2034, exhibiting a CAGR of 10.1% during the forecast period. Viscosupplementation is a medical procedure that involves the injection of hyaluronic acid-based substances into a joint, most commonly the knee, to relieve pain associated with osteoarthritis (OA). This treatment acts as a lubricant and shock absorber, enhancing joint function and comfort.

The market’s robust growth is primarily driven by the increasing prevalence of osteoarthritis, a growing aging population, and a shift toward minimally invasive treatments. As demand for non-surgical alternatives to joint replacement grows, viscosupplementation offers an effective, FDA-approved treatment path, especially in earlier stages of OA.

Market Segmentation

1. Viscosupplementation Market, Product Outlook (Revenue – USD Billion, 2020-2034)
   • Three Injection
   • Five Injection
   • Single Injection

 Viscosupplementation Market, End-UseOutlook (Revenue – USD Billion, 2020-2034)

4. Orthopedic Clinics/ASCs
5. Hospitals

Market Regional

• • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
    • Rest of Europe

Viscosupplementation Industry Developments

In July 2024, LG Chem announced that its partner, Yifan Pharmaceutical, had launched Synovian in China. Synovian, a single-dose intra-articular treatment for osteoarthritis, is marketed under the name Hyruan One. This launch marks a significant expansion in the treatment options available for osteoarthritis patients in China.

In November 2022, Anika Therapeutics, Inc., a leader in joint preservation, announced that it had successfully met the primary endpoint in the Phase III Study for Cingal. Cingal is designed to provide long-lasting pain relief for individuals with knee osteoarthritis (OA). Anika Therapeutics is now focused on securing FDA clearance for Cingal and introducing the product to the U.S. market.

In April 2022, Juniper Biologics and Kolon Life Sciences entered into a licensing agreement to develop and commercialize TissueGene-C low dose (TG-C LD), an investigational therapy aimed at non-surgical treatment for knee osteoarthritis through a single intra-articular injection. Under the terms of the agreement, Juniper will spearhead development and promotion of this gene therapy in the Asia Pacific, Middle East, and Africa regions, targeting medical professionals and hospitals.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/viscosupplement-market 

Market Trends

1. Rising Osteoarthritis Prevalence
   • OA is a leading cause of disability worldwide. As the global population ages, the incidence of OA is expected to rise significantly, directly increasing demand for viscosupplementation.
2. Preference for Minimally Invasive Procedures
   • Patients and providers alike are favoring procedures that are outpatient, less invasive, and allow for quicker recovery—aligning perfectly with viscosupplementation.
3. Product Innovation and Extended-Release Formulations
   • Advances in hyaluronic acid technologies, including cross-linked and extended-release formulations, are enhancing the efficacy and durability of injections, improving patient outcomes.
4. Expansion of Indications Beyond Knee OA
   • While knee OA dominates, viscosupplementation is gaining traction in hip and shoulder OA treatment. Clinical trials and off-label uses are expanding potential applications.
5. Favorable Regulatory and Reimbursement Environment
   • FDA approvals, CE markings, and expanding coverage by private insurers and Medicare are boosting market access and physician adoption.

Challenges

1. Limited Long-Term Efficacy
   • While effective for short-to-medium-term relief, some studies question the long-term benefits of viscosupplementation, especially in advanced OA stages.
2. High Treatment Costs
   • Cost can be a barrier, particularly in low- and middle-income countries where reimbursement may be limited or absent.
3. Competition from Alternative Therapies
   • Alternatives such as corticosteroid injections, physical therapy, platelet-rich plasma (PRP), stem cell therapy, and ultimately joint replacement, create competitive pressure.
4. Regulatory Scrutiny and Product Recalls
   • Regulatory compliance is critical. Any deviations or adverse event reports can lead to product recalls, damaging brand credibility.

Key Companies in the Viscosupplementation Market

Leading companies are investing in product innovation, strategic partnerships, and geographic expansion to gain market share:

• Anika Therapeutics, Inc.
• DePuy Synthes
• F.Hoffmann-La Roche Ltd.
• Ferring Pharmaceuticals B.V.
• Fidia Farmaceutici S.p.A
• LG Life Sciences Ltd.
• Lifecore Biomedical
• Sanofi
• Seikagaku Corp.
• Smith & Nephew PLC
• Zimmer Biomet

These players are focusing on mergers and acquisitions, product approvals, and distribution partnerships to broaden their customer reach and gain a competitive edge.

Conclusion

The global viscosupplementation market is set to experience strong growth, reaching USD 15.26 billion by 2034 from USD 6.39 billion in 2025, at a CAGR of 10.1%. As osteoarthritis cases rise and healthcare trends shift toward minimally invasive solutions, viscosupplementation will remain a key non-surgical option for joint pain management. With ongoing advancements in formulation, increasing market awareness, and expanding indications, the market is well-positioned for sustainable and dynamic growth over the next decade.

More Trending Latest Reports By Polaris Market Research:

Medical Devices Market

Crane Rental Market

Platelet Rich Plasma (PRP) Market

Hearing Aid Dispensers Market

Technical Textiles Market

Donkey Milk Market

North America Microencapsulation Market

3D Machine Vision Market